Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalTimes Interest Earned

Kiora Pharmaceuticals (KPRX) Equity Average (2016 - 2025)

Kiora Pharmaceuticals' Equity Average history spans 11 years, with the latest figure at $19.3 million for Q4 2025.

  • For Q4 2025, Equity Average fell 30.92% year-over-year to $19.3 million; the TTM value through Dec 2025 reached $19.3 million, down 30.92%, while the annual FY2025 figure was $20.9 million, 31.43% up from the prior year.
  • Equity Average reached $19.3 million in Q4 2025 per KPRX's latest filing, down from $22.3 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $34.0 million in Q2 2024 to a low of $6.8 million in Q3 2021.
  • Average Equity Average over 5 years is $16.7 million, with a median of $12.9 million recorded in 2022.
  • Peak YoY movement for Equity Average: soared 292.51% in 2024, then tumbled 32.61% in 2025.
  • A 5-year view of Equity Average shows it stood at $7.3 million in 2021, then soared by 32.81% to $9.6 million in 2022, then dropped by 26.29% to $7.1 million in 2023, then skyrocketed by 292.51% to $27.9 million in 2024, then crashed by 30.92% to $19.3 million in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Equity Average are $19.3 million (Q4 2025), $22.3 million (Q3 2025), and $22.9 million (Q2 2025).